Giovanni Lapadula - Publications

Italian Multicenter Real-World Study on the Twelve-Month Effectiveness, Safety, and Retention Rate of Guselkumab in Psoriatic Arthritis Patients.

Journal: Journal of clinical medicine

Published: March 09, 2025

Cascade of care for TB infection in persons newly diagnosed with HIV in Italy.

Journal: The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease

Published: October 29, 2024

Efficacy and retention rate of secukinumab in psoriatic arthritis across different clinical phenotypes: insights from the Italian GISEA Registry.

Journal: Therapeutic advances in musculoskeletal disease

Published: October 23, 2024

Drugs for treating infections caused by non-tubercular mycobacteria: a narrative review from the study group on mycobacteria of the Italian Society of Infectious Diseases and Tropical Medicine.

Journal: Infection

Published: October 30, 2023

Effectiveness and safety of filgotinib in rheumatoid arthritis patients: data from the GISEA registry.

Journal: Clinical and experimental rheumatology

Published: September 05, 2023

Rheumatoid Arthritis from Easy to Complex Disease: From the "2022 GISEA International Symposium".

Journal: Journal of clinical medicine

Published: February 20, 2023

Comorbidities in the Spondyloarthritis GISEA Cohort: an average treatment effect analysis on patients treated with bDMARDs.

Journal: Clinical and experimental rheumatology

Published: February 08, 2023

From Bench to Bedside in Rheumatoid Arthritis from the "2022 GISEA International Symposium".

Journal: Journal of clinical medicine

Published: November 14, 2022

Axial Spondyloarthritis: Reshape the Future-From the "2022 GISEA International Symposium".

Journal: Journal of clinical medicine

Published: October 20, 2022

Arthritis in Systemic Lupus Erythematosus: From 2022 International GISEA/OEG Symposium.

Journal: Journal of clinical medicine

Published: September 02, 2022

Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry.

Journal: Clinical rheumatology

Published: January 02, 2021

Tumor Necrosis Factor Inhibitor Monotherapy Versus Combination Therapy for the Treatment of Psoriatic Arthritis: Combined Analysis of European Biologics Databases.

Journal: The Journal of rheumatology

Published: March 18, 2020